Evidence map›Paper›PMID 23849222›Full record

ReviewTransplantation reviews (Orlando, Fla.)2013

Tofacitinab in renal transplantation.

Martin S Zand

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Transplantation reviews (Orlando, Fla.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Side Effects of Immunosuppressant Drugs After Liver Transplant.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Review
  4. JAK inhibitors for asthma.The Journal of allergy and clinical immunology · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Martin S ZandDepartment of Medicine, Division of Nephrology, University of Rochester Medical Center, Box 675, Rochester, NY 14642, USA. Martin_Zand@urmc.rochester.edu
University of Rochester Medical Center · US

Funding

Modeling B Cell Vaccine Responses in Transplant RecipientsR01AI069351 · NIAID · UNIVERSITY OF ROCHESTER · PI HYRIEN, OLLIVIER, ZAND, MARTIN S · 2007 to 2016
$3.7M
Modeling Immune Desensitization in Renal TransplantationR01AI098112 · NIAID · UNIVERSITY OF ROCHESTER · PI ZAND, MARTIN S · 2012 to 2016
$1.9M
NIAID NIH HHS R01 AI069351NIAID NIH HHS R01 AI098112
6 · The paper itself

Abstract

Tofacitinib (tositinib, CP-690,550) is a small molecule inhibitor of Janus associated kinases, primarily JAK3 and JAK2, which inhibits cytokine signaling through the IL-2Rγ chain. In this article, we review the mechanism of action of tofacitinib, and pre-clinical and clinical data regarding its use in solid organ transplantation thus far. It is hoped that tofacitinib may form the basis for calcineurin-free immunosuppression, improving renal function while eliminating calcineurin inhibitor renal toxicity. Current studies suggest that tofacitinib is an effective immunosuppressive agent for renal transplantation, but it's use in current protocols carries an increased risk of CMV, BK, and EBV viral infection, anemia and leukopenia, and post-transplant lymphoproliferative disorder.

Indexed as

Kidney TransplantationGraft RejectionHumansImmunosuppressive AgentsInfectionsPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolesRisk FactorsImmunosuppressive AgentsPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolestofacitinib

Identifiers

PMID23849222
PMCPMC3713609
OpenAlexW1988905531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.